BLAINTRAVITREALINJECTABLEPriority Review
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BEOVU (brolucizumab) is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) administered as an intravitreal injection for retinal diseases. It treats seven indications including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and polypoidal choroidal vasculopathy. The drug works by binding and inhibiting VEGF to reduce abnormal blood vessel growth and inflammation in the retina.
$0.602MPart D
PeakBEOVU is in peak lifecycle maturity with modest Part D utilization; the brand team is likely focused on market penetration against established VEGF competitors rather than rapid growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
Started Dec 2024
66 enrolled
Diabetic Macular Edema
Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema
Started Jul 2024
52 enrolled
Diabetic Macular Edema
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
Started Feb 2023
148 enrolled
Macular Polypoidal Choroidal Vasculopathy (PCV)
Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy
Started Jan 2023
36 enrolled
Age-Related Macular DegenerationPachychoroid Neovasculopathy
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
Started Sep 2022
438 enrolled
Neovascular Age-Related Macular Degeneration
Worked on BEOVU at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.